How Fast Does Zepbound Work? Your Complete Results Timeline

The short answer: Most people notice less hunger within the first few weeks, but the scale moves slowly at first because the starting dose is only a first step. In the largest Zepbound (tirzepatide) trial, average weight loss reached roughly 15% to 22% of body weight at 72 weeks, depending on the dose, and it kept growing for more than a year. Your own pace will depend on your dose, your side effects, and how steadily you take the medicine.

If you are thinking about starting Zepbound, or you have just started and are wondering whether it is working, this guide explains what the research shows and what you can reasonably expect at each stage. It covers the dosing schedule that sets the pace, a stage-by-stage timeline, the main clinical trials, the factors that make one person’s results differ from another’s, and the side effects and safety points you should know before your first injection. Everything here is general education. Your own plan should come from your prescribing clinician.

Why the dosing schedule sets the pace

Zepbound is designed to be started low and raised slowly. The first four weeks are at 2.5 mg once a week. According to the prescribing information, that dose is meant to help your body adjust, and it is not intended as a long-term treatment dose. After four weeks the dose goes up to 5 mg. From there it can be raised in 2.5 mg steps, with at least four weeks at each step, until you reach the dose that works best for you. For weight reduction, the maintenance doses are 5 mg, 10 mg, or 15 mg once weekly, and 15 mg is the maximum.

This slow climb matters for your timeline. Because each step takes at least four weeks, the earliest anyone can reach 15 mg is around week 21. Many people never need the top dose. A clinician may hold you at a lower dose if you are losing weight well and tolerating it, or if side effects are hard to manage. That is why two people who start on the same day can look quite different at month three.

Step	Weekly dose	Earliest timing	What it is for
Starter	2.5 mg	Weeks 1–4	Getting used to the medicine. Not a maintenance dose.
Step 2	5 mg	Weeks 5–8	First maintenance dose. Some people stay here.
Step 3	7.5 mg	Weeks 9–12	A step on the way to higher maintenance doses.
Step 4	10 mg	Weeks 13–16	Maintenance dose.
Step 5	12.5 mg	Weeks 17–20	A step on the way to 15 mg.
Step 6	15 mg	Week 21 or later	Highest dose and maintenance option.

Standard Zepbound dose escalation for weight reduction. Each step lasts at least 4 weeks, and your clinician may go slower. Source: prescribing information.

Two practical points from the label are worth knowing. If you miss a dose, you can take it within four days (96 hours) of the missed day. If more than four days have passed, skip it and take the next dose on your regular day. You can also change your injection day, as long as at least three days (72 hours) separate the two doses. Do not take Zepbound together with another tirzepatide product or with any GLP-1 medicine, because the label advises against that combination.

The Zepbound results timeline: what to expect at each stage

The weight figures below come from the SURMOUNT-1 trial of 2,539 adults with obesity or overweight and no diabetes, where participants averaged about 231 pounds (BMI 38) at the start and everyone also received lifestyle counseling. The early and mid-trial numbers are approximate readings of the published weight-over-time graph (the efficacy estimate), so treat them as typical values, not promises. The 72-week numbers are the exact published results, and we list them in the next section.

Weeks 1–4: starting low and adjusting

During the first month you are on 2.5 mg, and this is mostly a tolerance-building period. Many people notice that food feels less urgent or that they feel full sooner, and some notice it within the first week or two. On the scale, the trial average at four weeks was a loss of roughly 3% of body weight in every dose group, which comes to about seven pounds for the typical participant. Plenty of people lose less than that, or more, and both are normal.

Side effects are most likely during this early window and again after each dose increase. Mild nausea, loose stools, constipation, and heartburn are the usual ones, and they tend to ease as your body adapts. If you are in week three and have only lost a couple of pounds, you are on track, since the dose that drives the larger results has not been reached yet.

Months 2–3 (weeks 5–12): the dose steps up

In the second and third months you typically move from 5 mg to 7.5 mg or 10 mg, if your clinician agrees that you are ready. This is when many people say the medicine “really kicks in.” In SURMOUNT-1, average weight loss was about 6% at eight weeks and roughly 8% to 9% at twelve weeks. Weight was falling fastest during the first several months of the trial, and many people also describe a clearer sense of fullness and fewer cravings in this stretch.

It is also when side effects can flare briefly, since each increase is a new adjustment. Eating smaller portions, stopping before you feel stuffed, and limiting very fatty or greasy meals can help. Our guide to the side effects of Zepbound explains what is common, what is not, and when to call us.

Months 4–6 (weeks 13–26): building toward your maintenance dose

By months four to six, many people are on 10 mg or are approaching 15 mg. The trial curves for the three doses ran almost on top of one another until about week 12 and then began to separate. By week 24, average loss was roughly 12% in the 5 mg group and about 14% to 15% in the 10 mg and 15 mg groups. At week 20, the two higher-dose groups combined had lost an average of 12.8 kg (about 28 pounds), compared with 2.7 kg (about 6 pounds) on placebo. The weight is still coming off, but the curve begins to flatten gradually. People often notice that clothes fit differently, that their blood pressure or blood sugar numbers are better, and that portions that once felt normal now feel like too much.

This is also a common time for the first plateau. A stall of a week or two is normal as your body adapts to a lower weight. If it lasts longer, our guides on why weight loss stalls and how to break through a plateau walk through the causes, from dose and sleep to protein intake and strength training.

Months 7–12 (weeks 27–52): approaching your peak pace

During the second half of the first year, the trial participants were still losing weight, just more slowly. By week 48, average loss was about 15% on 5 mg, 19% on 10 mg, and 21% on 15 mg. This is the period when many people settle into a dose and a routine. The main work shifts from losing to building habits that you can keep for the long run: regular meals with enough protein, strength training, steady sleep, and a plan for travel, holidays, and stressful stretches.

Beyond a year: weeks 53–72 and after

Seventy-two weeks is about 16 to 17 months, not one year. In SURMOUNT-1, the 5 mg curve had leveled off by about week 60, while the 10 mg and 15 mg groups were still inching down at week 72, by roughly half a percentage point over the last 12 weeks. The study did not follow people long enough to say how much further weight would have fallen. Trial data also show what happens when people stop, which we cover below.

What the clinical trials show

SURMOUNT-1: adults with obesity, without diabetes

SURMOUNT-1 is the trial behind most of the numbers you see online. It was published in the New England Journal of Medicine in 2022 and randomized 2,539 adults to tirzepatide 5 mg, 10 mg, 15 mg, or placebo once weekly for 72 weeks, along with a reduced-calorie diet and increased physical activity. The average participant was about 45 years old, and two-thirds were women. Trials report weight loss in two ways, and it helps to know the difference. One method, the treatment-regimen estimate, counts everyone who was assigned to a treatment, including people who stopped the drug or took it irregularly. The other, the efficacy estimate, describes what happened while people actually took it. Both are legitimate, and for people on tirzepatide the second one is a bit higher.

Group (72 weeks)	Treatment-regimen estimate	Efficacy estimate
Tirzepatide 5 mg	15.0%	16.0%
Tirzepatide 10 mg	19.5%	21.4%
Tirzepatide 15 mg	20.9%	22.5%
Placebo	3.1%	2.4%

SURMOUNT-1 average weight change at 72 weeks. Source: Jastreboff et al., NEJM 2022.

Group	5% or more	10% or more	15% or more	20% or more
Tirzepatide 5 mg	85% / 89%	69% / 73%	48% / 50%	30% / 32%
Tirzepatide 10 mg	89% / 96%	78% / 86%	67% / 74%	50% / 56%
Tirzepatide 15 mg	91% / 96%	84% / 90%	71% / 78%	57% / 63%
Placebo	35% / 28%	19% / 14%	9% / 6%	3% / 1%

Share of participants reaching each weight-loss target at 72 weeks, shown as treatment-regimen / efficacy estimate and rounded to whole numbers. Source: Jastreboff et al., NEJM 2022 (Figure 1C and 1D).

The headline figure of 22.5% that you see so often is the efficacy result at the 15 mg dose. The treatment-regimen result at the same dose is 20.9%. Both are impressive, and both come with a caveat: they are averages. Some participants lost much more and some lost much less. In the trial, between 85% and 91% of people on tirzepatide lost at least 5% of their body weight (treatment-regimen estimate), compared with 34.5% on placebo, and between 30% and 57% lost at least 20%, compared with 3.1% on placebo. For a more detailed look at the original release, see the Lilly topline announcement.

SURMOUNT-2: adults with obesity and type 2 diabetes

People with type 2 diabetes usually lose less weight than people without it, and SURMOUNT-2 shows that. In this 72-week trial of 938 adults, published in The Lancet in 2023, the average weight loss was 12.8% on 10 mg and 14.7% on 15 mg using the treatment-regimen estimate, and 13.4% and 15.7% using the efficacy estimate. Placebo groups lost about 3%. If you have diabetes, a realistic target is therefore lower than the SURMOUNT-1 figures, although the medicine also improves blood sugar.

SURMOUNT-4: what happens if you stop

SURMOUNT-4 asked what happens after the initial weight loss. All participants took tirzepatide for 36 weeks and lost an average of about 21%. They were then randomly assigned to keep taking it or switch to placebo. Over the next 52 weeks, the people who continued lost a further 5.5%, while those who switched to placebo regained 14.0% of their body weight. About 90% of those who continued kept at least 80% of their loss, compared with about 17% of those who stopped. The findings were published in JAMA in 2024. We cover the practical side in what happens after stopping Wegovy or Zepbound.

SURMOUNT-5: Zepbound compared with Wegovy

In a head-to-head trial of 751 adults with obesity and no diabetes, tirzepatide produced an average weight loss of 20.2% at 72 weeks, versus 13.7% for semaglutide. Fewer people on tirzepatide stopped treatment because of stomach side effects (2.7%, versus 5.6%). We explain the study in our Zepbound vs. Wegovy head-to-head article, and the newer Wegovy 7.2 mg dose is discussed separately.

Why your results may look different

Averages hide a lot of variation. Several things shape how quickly you lose weight, and most of them are things you and your clinician can work on together.

The first is dose and how fast you can climb. Someone who tolerates each step and reaches a higher maintenance dose will usually lose more than someone who stays at 5 mg, and a person who needs a slower escalation will see a later start. The second is consistency. Missing injections or stretching the interval between them lets the effect fade, and the trial results assume steady weekly dosing. The third is your starting point. People with a higher starting weight lose more pounds, while the percentage of body weight lost is generally similar across weight ranges. Other health conditions matter too, as seen above: people with type 2 diabetes lose less on average. Regular exercise will typically speed weight loss.

Finally, daily habits and other medicines play a role. Eating enough protein, doing resistance exercise, sleeping well, and managing stress all affect both how much weight you lose and how much of it is fat rather than muscle. If you want a practical plan, our guide on maximizing weight loss on Zepbound or Wegovy lays out the details. Patients also ask about creatine; our article on creatine and GLP-1 medications explains what the research does and does not show.

Making the first month count

Before you start, write down your weight, your waist and other measurements, and take a few photos. These baselines are useful because the scale can hide progress, especially early on. Choose an injection day that fits your weekly schedule, and set a reminder so that you can take it the same day each week.

Eating well matters more than it might seem. Smaller, more frequent meals can help if you are nauseated, and greasy or very rich foods are common triggers. Because your appetite will be lower, it helps to plan meals around protein, vegetables, and other nutrient-dense foods so that you are not undereating on the foods your body needs. A joint advisory from several obesity and nutrition societies calls for adequate protein and strength training to protect lean mass during GLP-1 treatment. The right protein amount depends on your size, kidney health, and goals, so ask your clinician, and see our article on muscle loss and GLP-1 medicines for the evidence.

Drink fluids regularly through the day. Vomiting and diarrhea can lead to dehydration, and the label warns that severe dehydration can contribute to kidney problems in some people, particularly while the dose is rising. If you can’t keep fluids down, call us rather than waiting. Finally, track more than the scale: how clothes fit, your energy, your blood pressure, and how often food is on your mind.

Side effects and safety

Zepbound is a prescription medicine, and it is not right for everyone. The label carries a boxed warning about thyroid C-cell tumors, which were seen in rats. It is not known whether Zepbound causes these tumors in people, but the medicine should not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. It should also not be used by anyone with a serious allergy to tirzepatide or its ingredients.

The most common side effects are stomach-related. In the weight-reduction trials, about 56% of people on Zepbound had a gastrointestinal side effect, compared with 30% on placebo. By dose, nausea affected about 25% to 29% of people (8% on placebo), diarrhea 19% to 23% (8%), constipation 11% to 17% (5%), vomiting 8% to 13% (2%), and abdominal pain and indigestion about 9% to 10% each. Most of these happened during dose increases and eased over time. In SURMOUNT-1, between 4.3% and 7.1% of people on tirzepatide stopped treatment because of side effects, compared with 2.6% on placebo. Injection-site reactions (6% to 8%), fatigue (5% to 7%), and hair loss (4% to 5%, versus 1% on placebo) were also reported. For more about the hair-related findings, see our article on GLP-1 medicines and your skin and hair.

Less common but more serious problems include pancreatitis (confirmed in one person in each tirzepatide group and one on placebo in SURMOUNT-1), gallbladder disease (reported in 0.8% to 1.7% on tirzepatide and 0.8% on placebo), acute kidney injury linked to dehydration, severe allergic reactions, and, in people with diabetic eye disease, worsening of retinopathy. If you have type 1 diabetes you should only take GLP-1 medications under the care of a diabetes specialist. We do not prescribe GLP-1 medications to patients with type 1 diabetes, or patients who take insulin.  The label also advises telling your care team about any planned surgery or procedure that needs anesthesia or deep sedation, and it does not recommend Zepbound for people with severe gastroparesis.

One more point that surprises many women: Zepbound may make birth control pills less reliable. The label advises switching to a non-oral method, or adding a barrier method, for four weeks after you start and for four weeks after each dose increase. Call us right away for severe stomach pain, persistent vomiting, a lump or swelling in the neck, trouble swallowing, or signs of an allergic reaction. Our full side-effects guide covers all of this in more depth.

Benefits beyond the scale

Weight is only part of the picture. In SURMOUNT-1, the two higher-dose groups combined lowered systolic blood pressure by an average of 7.2 mm Hg, compared with 1.0 mm Hg on placebo. Triglycerides fell by about 25% (versus about 6% on placebo), fasting insulin fell by about 43% (versus about 7%), and HDL, the “good” cholesterol, rose by about 8%. Waist circumference dropped by 14 to 18.5 cm (roughly 5.5 to 7.3 inches) across the three doses, compared with 4 cm on placebo. Our article on blood pressure, cholesterol, and the SURMOUNT triple endpoint goes through the related data. Zepbound is also FDA-approved for adults with obesity and moderate-to-severe obstructive sleep apnea, which we cover in Zepbound and sleep apnea. For long-term heart outcomes, see the three-year SURMOUNT-1 follow-up.

Some benefits that are often mentioned online, such as better mood, better sleep, and less joint pain, make intuitive sense when someone loses weight, but we have not cited trial data for them here and so we do not list them as proven effects of the medicine.

Common questions about how fast Zepbound works

I’m in week 3 and have only lost 2 pounds. Is that normal?

Yes. You are still on the starter dose, and the first month is mainly about tolerance. In the trial the average loss at about four weeks was only a few percent of body weight, and the bigger changes came after the dose was raised.

When will I reach my goal weight?

It depends on your starting weight, your goal, and your dose. In SURMOUNT-1, weight was still falling at the end of the 72-week study period in the higher-dose groups, so many people take well over a year. Setting a goal in terms of percent of body weight, and revisiting it every few months with your clinician, is usually more useful than a fixed date.

What if I miss a dose?

According to the label, take it as soon as you remember if it is within four days (96 hours) of the missed dose. If more than four days have passed, skip that dose and take the next one on your usual day. Do not double up.

Do I have to get to 15 mg?

No. The label lists 5 mg, 10 mg, and 15 mg as maintenance doses for weight reduction. The right dose is the one that gives you good results with side effects you can live with, and your clinician will help you find it.

My weight loss stalled. What should I do?

A pause of a week or two is common. If your weight hasn’t moved for several weeks, that is a good time to talk with your clinician about your dose, your protein and activity, your sleep, and any other medicines. Our guide to breaking through a plateau covers the options.

What happens if I stop Zepbound?

In SURMOUNT-4, people who switched to placebo regained about 14% of their body weight over the next year, while those who kept going lost a little more. Weight regain after stopping is common, which is why treatment is usually viewed as long-term. Read more in what happens after stopping Wegovy or Zepbound.

Will my insurance cover it?

Coverage varies widely by plan and often requires prior authorization. We explain how the process works in our guide to insurance and prior authorization for weight loss medications.

The bottom line

Zepbound works gradually. Expect reduced appetite and a modest drop on the scale in the first month, faster loss through months two and three as the dose rises, and continued but slower loss through the first year and beyond. In the largest trial, average results at 72 weeks ranged from about 15% to 22% of body weight depending on the dose and how results were counted, and people with type 2 diabetes lost somewhat less. The people who did best kept taking the medicine consistently, and stopping it led to substantial weight regain.

If you would like to know whether Zepbound is appropriate for you, we are happy to talk it through. You can read more about the medication itself or ask us about the dosing plan that fits your situation.

If you take Zepbound or Wegovy and would like help with your eating plan, protein goals or side effects, or you are thinking about starting, we can help. Book an appointment or call or text us at (703) 359-9200.

BeLite sees patients from across Northern Virginia and Maryland. See our pages for Annandale, Burke, Falls Church, Springfield, Vienna and Oakton for directions and hours.

Last medically reviewed: November 1, 2026. This article is for general education and is not a substitute for medical advice.

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
2. Eli Lilly and Company. Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight (SURMOUNT-1 topline release, April 28, 2022). Lilly investor site
3. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613–626. PubMed 37385275; doi:10.1016/S0140-6736(23)01200-X
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394
6. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. pi.lilly.com